Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review

References

• Kane MA. Analysis, occurrence, and function of 9-cis-retinoic acid. Biochim Biophys Acta. 2012;1821:10–20.
   PubMed Web of Science ®Google Scholar
• Hayden LJ, Hawk SN, Sih TR, et al. Metabolic conversion of retinol to retinoic acid mediates the biological responsiveness of human mammary epithelial cells to retinol. J Cell Physiol. 2001;186:437–447.
   PubMed Web of Science ®Google Scholar
• Zusi FC, Lorenzi MV, Vivat-Hannah V. Selective retinoids and rexinoids in cancer therapy and chemoprevention. Drug Discov Today. 2002;7:1165–1174.
   PubMed Web of Science ®Google Scholar
• Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996;10:940–954.
   PubMed Web of Science ®Google Scholar
• Dollé P, Niederreither K. The retinoids: biology, biochemistry, and disease. Hoboken (NJ): John Wiley & Sons; 2015.
   Google Scholar
• Minucci S, Leid M, Toyama R, et al. Retinoid X receptor (RXR) within the RXR-retinoic acid receptor heterodimer binds its ligand and enhances retinoid-dependent gene expression. Mol Cell Biol. 1997;17:644–655.
   PubMed Web of Science ®Google Scholar
• Lane MA, Bailey SJ. Role of retinoid signalling in the adult brain. Prog Neurobiol. 2005;75:275–293.
   PubMed Web of Science ®Google Scholar
• Hauksdottir H, Farboud B, Privalsky ML. Retinoic acid receptors beta and gamma do not repress, but instead activate target gene transcription in both the absence and presence of hormone ligand. Mol Endocrinol. 2003;17:373–385.
   PubMed Web of Science ®Google Scholar
• Nagy L, Thomázy VA, Saydak MM, et al. The promoter of the mouse tissue transglutaminase gene directs tissue-specific, retinoid-regulated and apoptosis-linked expression. Cell Death Differ. 1997;4:534–547.
   PubMed Web of Science ®Google Scholar
• Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev. 2001;81:1269–1304.
   PubMed Web of Science ®Google Scholar
• Shaw N, Elholm M, Noy N. Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor beta/delta. J Biol Chem. 2003;278:41589–41592.
   PubMed Web of Science ®Google Scholar
• Oliveira ACP, Bertollo CM, Rocha LTS, et al. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur J Pharmacol. 2007;561:194–201.
   PubMed Web of Science ®Google Scholar
• Peters JM, Lee SS, Li W, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol. 2000;20:5119–5128.
   PubMed Web of Science ®Google Scholar
• Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20:649–688.
   PubMed Web of Science ®Google Scholar
• Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer. 2001;1:181–193.
   PubMed Web of Science ®Google Scholar
• Adhikary T, Brandt DT, Kaddatz K, et al. Inverse PPARβ/δ agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion. Oncogene. 2013;32:5241–5252.
   PubMed Web of Science ®Google Scholar
• Tan NS, Michalik L, Noy N, et al. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev. 2001;15:3263–3277.
   PubMed Web of Science ®Google Scholar
• Schug TT, Berry DC, Shaw NS, et al. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell. 2007;129:723–733.
   PubMed Web of Science ®Google Scholar
• Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev. 2006;58:760–772.
   PubMed Web of Science ®Google Scholar
• Huang P, Chandra V, Rastinejad F. Retinoic acid actions through mammalian nuclear receptors. Chem Rev. 2014;114:233–254.
   PubMed Web of Science ®Google Scholar
• Duong V, Rochette-Egly C. The molecular physiology of nuclear retinoic acid receptors. From health to disease. Biochim Biophys Acta. 2011;1812:1023–1031.
   PubMed Web of Science ®Google Scholar
• Sun S-Y, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol. 2002;41:41–55.
   PubMed Web of Science ®Google Scholar
• Brand NJ, Petkovich M, Chambon P. Characterization of a functional promoter for the human retinoic acid receptor-alpha (hRAR-alpha). Nucleic Acids Res. 1990;18:6799–6806.
   PubMed Web of Science ®Google Scholar
• De The H, Marchio A, Tiollais P, et al. Differential expression and ligand regulation of the retinoic acid receptor alpha and beta genes. EMBO J. 1989;8:429–433.
   PubMed Web of Science ®Google Scholar
• Leroy P, Krust A, Zelent A, et al. Multiple isoforms of the mouse retinoic acid receptor alpha are generated by alternative splicing and differential induction by retinoic acid. EMBO J. 1991;10:59–69.
   PubMed Web of Science ®Google Scholar
• Wang S, Tricot G, Shi L, et al. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood. 2009;114:600–607.
   PubMed Web of Science ®Google Scholar
• Kastner P, Lawrence HJ, Waltzinger C, et al. Positive and negative regulation of granulopoiesis by endogenous RARalpha. Blood. 2001;97:1314–1320.
   PubMed Web of Science ®Google Scholar
• Labrecque J, Allan D, Chambon P, et al. Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptors alpha1 and gamma. Blood. 1998;92:607–615.
   PubMed Web of Science ®Google Scholar
• Oren T, Sher JA, Evans T. Hematopoiesis and retinoids: development and disease. Leuk Lymphoma. 2003;44:1881–1891.
   PubMed Web of Science ®Google Scholar
• Zhu J, Heyworth CM, Glasow A, et al. Lineage restriction of the RARalpha gene expression in myeloid differentiation. Blood. 2001;98:2563–2567.
   PubMed Web of Science ®Google Scholar
• Chen SJ, Wang ZY, Chen Z. Acute promyelocytic leukemia: from clinic to molecular biology. Stem Cells. 1995;13:22–31.
   PubMed Web of Science ®Google Scholar
• Schenk T, Stengel S, Zelent A. Unlocking the potential of retinoic acid in anticancer therapy. Br J Cancer. 2014;111:2039–2045.
   PubMed Web of Science ®Google Scholar
• Bruck N, Vitoux D, Ferry C, et al. A coordinated phosphorylation cascade initiated by p38MAPK/MSK1 directs RARalpha to target promoters. EMBO J. 2009;28:34–47.
   PubMed Web of Science ®Google Scholar
• Soprano DR, Qin P, Soprano KJ. Retinoic acid receptors and cancers. Annu Rev Nutr. 2004;24:201–221.
   PubMed Web of Science ®Google Scholar
• Khetchoumian K, Teletin M, Tisserand J, et al. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet. 2007;39:1500–1506.
   PubMed Web of Science ®Google Scholar
• Sodhi RK, Singh N. Retinoids as potential targets for Alzheimer’s disease. Pharmacol Biochem Behav. 2014;120:117–123.
   PubMed Web of Science ®Google Scholar
• Houle B, Pelletier M, Wu J, et al. Fetal isoform of human retinoic acid receptor beta expressed in small cell lung cancer lines. Cancer Res. 1994;54:365–369.
   PubMed Web of Science ®Google Scholar
• Toulouse A, Morin J, Pelletier M, et al. Structure of the human retinoic acid receptor beta 1 gene. Biochim Biophys Acta. 1996;1309:1–4.
   PubMed Web of Science ®Google Scholar
• Van Der Leede BJ, Folkers GE, Kruyt FA, et al. Genomic organization of the human retinoic acid receptor beta 2. Biochem Biophys Res Commun. 1992;188:695–702.
   PubMed Web of Science ®Google Scholar
• Alvarez S, Germain P, Alvarez R, et al. Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor. Int J Biochem Cell Biol. 2007;39:1406–1415.
   PubMed Web of Science ®Google Scholar
• Xu X-C. Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett. 2007;253:14–24.
   PubMed Web of Science ®Google Scholar
• Petty WJ, Li N, Biddle A, et al. A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J Natl Cancer Inst. 2005;97:1645–1651.
   PubMedGoogle Scholar
• Ivanova T, Petrenko A, Gritsko T, et al. Methylation and silencing of the retinoic acid receptor-β2 gene in cervical cancer. BMC Cancer. 2002;2:2–4.
   PubMed Web of Science ®Google Scholar
• Youssef EM, Lotan D, Issa JP, et al. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res. 2004;10:1733–1742.
   PubMed Web of Science ®Google Scholar
• Youssef EM, Estecio MRH, Issa J-PJ. Methylation and regulation of expression of different retinoic acid receptor beta isoforms in human colon cancer. Cancer Biol Ther. 2004;3:82–86.
   PubMed Web of Science ®Google Scholar
• Muñiz-Hernández S, Hernández-Pedro N, Macedo-Pérez OE, et al. Alterations in retinoic acid receptors in non-small cell lung cancer and their clinical implications. J Cancer Ther. 2015;6:648–664.
   Google Scholar
• Widschwendter M, Berger J, Hermann M, et al. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst. 2000;92:826–832.
   PubMed Web of Science ®Google Scholar
• Nakayama T, Watanabe M, Yamanaka M, et al. The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab Invest. 2001;81:1049–1057.
   PubMed Web of Science ®Google Scholar
• Berard J, Laboune F, Mukuna M, et al. Lung tumors in mice expressing an antisense RARbeta2 transgene. Faseb J. 1996;10:1091–1097.
   PubMed Web of Science ®Google Scholar
• Faria TN, Mendelsohn C, Chambon P, et al. The targeted disruption of both alleles of RARbeta(2) in F9 cells results in the loss of retinoic acid-associated growth arrest. J Biol Chem. 1999;274:26783–26788.
   PubMed Web of Science ®Google Scholar
• Sirchia SM, Ren M, Pili R, et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 2002;62:2455–2461.
   PubMed Web of Science ®Google Scholar
• Nagpal S, Zelent A, Chambon P. RAR-beta 4, a retinoic acid receptor isoform is generated from RAR-beta 2 by alternative splicing and usage of a CUG initiator codon. Proc Natl Acad Sci U S A. 1992;89:2718–2722.
   PubMed Web of Science ®Google Scholar
• Chen LI, Sommer KM, Swisshelm K. Downstream codons in the retinoic acid receptor beta −2 and beta −4 mRNAs initiate translation of a protein isoform that disrupts retinoid-activated transcription. J Biol Chem. 2002;277:35411–35421.
   PubMed Web of Science ®Google Scholar
• Swift CB, Hays JL, Petty WJ. Distinct functions of retinoic acid receptor beta isoforms: implications for targeted therapy. Endocr Metab Immune Disord Drug Targets. 2008;8:47–50.
   PubMedGoogle Scholar
• Sommer KM, Chen LI, Treuting PM, et al. Elevated retinoic acid receptor beta(4) protein in human breast tumor cells with nuclear and cytoplasmic localization. Proc Natl Acad Sci U S A. 1999;96:8651–8656.
   PubMed Web of Science ®Google Scholar
• Nagpal S, Saunders M, Kastner P, et al. Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. Cell. 1992;70:1007–1019.
   PubMed Web of Science ®Google Scholar
• Lehmann JM, Hoffmann B, Pfahl M. Genomic organization of the retinoic acid receptor gamma gene. Nucleic Acids Res. 1991;19:573–578.
   PubMed Web of Science ®Google Scholar
• Lehmann JM, Zhang XK, Pfahl M. RAR gamma 2 expression is regulated through a retinoic acid response element embedded in Sp1 sites. Mol Cell Biol. 1992;12:2976–2985.
   PubMed Web of Science ®Google Scholar
• Husmann M, Lehmann J, Hoffmann B, et al. Antagonism between retinoic acid receptors. Mol Cell Biol. 1991;11:4097–4103.
   PubMed Web of Science ®Google Scholar
• Xu XC, Wong WY, Goldberg L, et al. Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis. Cancer Res. 2001;61:4306–4310.
   PubMed Web of Science ®Google Scholar
• Yan TD, Wu H, Zhang HP, et al. Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma. Cancer Res. 2010;70:2285–2295.
   PubMed Web of Science ®Google Scholar
• Purton LE, Dworkin S, Olsen GH, et al. RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J Exp Med. 2006;203:1283–1293.
   PubMed Web of Science ®Google Scholar
• Wang W, Yang J, Liu H, et al. Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1. Proc Natl Acad Sci U S A. 2011;108:18283–18288.
   PubMed Web of Science ®Google Scholar
• Gehin M, Vivat V, Wurtz JM, et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem Biol. 1999;6:519–529.
   PubMed Web of Science ®Google Scholar
• Alvarez S, Bourguet W, Gronemeyer H, et al. Retinoic acid receptor modulators: a perspective on recent advances and promises. Expert Opin Ther Pat. 2011;21:55–63.
   PubMed Web of Science ®Google Scholar
• Le Maire A, Teyssier C, Erb C, et al. A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor. Nat Struct Mol Biol. 2010;17:801–807.
   PubMed Web of Science ®Google Scholar
• Germain P, Gaudon C, Pogenberg V, et al. Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. Chem Biol. 2009;16:479–489.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Cicconi L, Breccia M. Current standard treatment of adult acute promyelocytic leukaemia. Br J Haematol. 2016;172:841–854.
   PubMed Web of Science ®Google Scholar
• Azoulay L, Blais L, Koren G, et al. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. J Clin Psychiatry. 2008;69:526–532.
   PubMed Web of Science ®Google Scholar
• D’Erme AM, Pinelli S, Cossidente A, et al. Association between isotretinoin and mood changes: myth or reality? An updated overview. Int J Dermatol. 2013;52:499–500.
   PubMed Web of Science ®Google Scholar
• Gnanaraj P, Karthikeyan S, Narasimhan M, et al. Decrease in “Hamilton rating scale for depression” following isotretinoin therapy in acne: an open-label prospective study. Indian J Dermatol. 2015;60:461–464.
   PubMed Web of Science ®Google Scholar
• Ormerod AD, Campalani E, Goodfield MJ. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol. 2010;162:952–963.
   PubMed Web of Science ®Google Scholar
• Henney JE. New drug for refractory cutaneous t-cell lymphoma. JAMA. 2000;283:1131.
   PubMed Web of Science ®Google Scholar
• Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999;340:1075–1079.
   PubMed Web of Science ®Google Scholar
• Smit JWA, Stokkel MPM, Pereira AM, et al. Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. J Clin Endocrinol Metab. 2007;92:2496–2499.
   PubMed Web of Science ®Google Scholar
• Burger AR, Iwata K, Granger SP, et al. Skin care compositions containing certain cyclic aliphatic unsaturated compounds and retinol or retinyl ester. US5759556A. 1998.
   Google Scholar
• Burger AR, Zhang KH, Granger SP, et al. Skin care compositions containing geranyl geraniol and retinol or retinyl esters. US5756109A. 1998.
   Google Scholar
• Granger SP, Rawlings AV, Scott IR Skin care compositions containing an amide of a hydroxy fatty acid and a retinoid. US5747051A. 1998.
   Google Scholar
• Granger SP, Rawlings AV, Scott IR Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester. US5716627A. 1998.
   Google Scholar
• Granger SP, Rawlings AV, Scott IR Skin care compositions containing fatty acid amides and retinol or retinyl ester. US5811110A. 1998.
   Google Scholar
• Granger SP, Rawlings AV, Scott IR Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester. EP0745375B1. 1996.
   Google Scholar
• Granger SP, Rawlings AV, Scott IR Skin care compositions containing fatty acid amides and retinol or retinyl ester. US5599548. 1997.
   Google Scholar
• Granger SP, Rawlings AV, Scott IR Skin care compositions containing an n-substituted fatty acid amide and retinol or retinyl ester. US5955092A. 1999.
   Google Scholar
• Corey J, Dorogi PL, Meyers AJ, et al. Cosmetic composition with a retinol fatty acid ester. US5885595A. 1999.
   Google Scholar
• Granger SP, Rawlings AV, Scott IR Skin care compositions containing melinamide and a retinoid. US5693330A. 1997.
   Google Scholar
• Granger SP, Scott IR, Donovan RM, et al. Method for Treating Skin with Retinoids and Retinoid Boosters. US20140050676A1. 2014.
   Google Scholar
• Lengfelder E, Saussele S, Weisser A, et al. Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hematol. 2005;56:261–274.
   PubMed Web of Science ®Google Scholar
• Altucci L, Rossin A, Raffelsberger W, et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med. 2001;7:680–686.
   PubMed Web of Science ®Google Scholar
• Clarke N, Jimenez-Lara AM, Voltz E, et al. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J. 2004;23:3051–3060.
   PubMed Web of Science ®Google Scholar
• Patatanian E, Thompson DF. Retinoic acid syndrome: a review. J Clin Pharm Ther. 2008;33:331–338.
   PubMed Web of Science ®Google Scholar
• Churchman ML, Low J, Qu C, et al. Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia. Cancer Cell. 2015;28:343–356.
   PubMed Web of Science ®Google Scholar
• Dragnev KH, Ma T, Cyrus J, et al. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila). 2011;4:818–828.
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Assaf C, Bagot M, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol. 2007;157:433–440.
   PubMed Web of Science ®Google Scholar
• Olson ML, Shedd DP. Disability and rehabilitation in head and neck cancer patients after treatment. Head Neck Surg. 1978;1:52–58.
   PubMedGoogle Scholar
• Dragnev KH, Petty WJ, Shah SJ, et al. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res. 2007;13:1794–1800.
   PubMed Web of Science ®Google Scholar
• Chen CF, Goyette P, Lohnes D. RARgamma acts as a tumor suppressor in mouse keratinocytes. Oncogene. 2004;23:5350–5359.
   PubMed Web of Science ®Google Scholar
• Gudas LJ, Tang XH, Osei-Safro K, et al. Combination therapy for head and neck cancer. WO2015138354A1. 2015.
   Google Scholar
• Tang X-H, Osei-Sarfo K, Urvalek AM, et al. Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. Proc Natl Acad Sci U S A. 2014;111:8907–8912.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148:399–408.
   PubMed Web of Science ®Google Scholar
• Eckert AW, Lautner MH, Schutze A, et al. Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. J Oral Pathol Med. 2010;39:313–317.
   PubMed Web of Science ®Google Scholar
• Ueda G, Sunakawa H, Nakamori K, et al. Aberrant expression of beta- and gamma-catenin is an independent prognostic marker in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2006;35:356–361.
   PubMed Web of Science ®Google Scholar
• Pannone G, Bufo P, Santoro A, et al. WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors. Oncol Rep. 2010;24:1035–1041.
   PubMed Web of Science ®Google Scholar
• Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. 2003;22:7305–7315.
   PubMed Web of Science ®Google Scholar
• Rao R, Balusu R, Fiskus W, et al. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther. 2012;11:973–983.
   PubMed Web of Science ®Google Scholar
• Fortunati N, Catalano MG, Marano F, et al. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS). Breast Cancer Res Treat. 2010;124:667–675.
   PubMed Web of Science ®Google Scholar
• Emionite L, Galmozzi F, Grattarola M, et al. Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines. Anticancer Res. 2004;24:4019–4024.
   PubMed Web of Science ®Google Scholar
• Miller WH, Gleason J, Mader S Hybrid molecule having mixed retinoic acid receptor agonism and histone deacetylase inhibitory properties. US20140051760A1. 2014.
   Google Scholar
• Murphy MP, LeVine H. Alzheimer’s disease and the β-amyloid peptide. J Alzheimers Dis. 2010;19:311.
   PubMed Web of Science ®Google Scholar
• Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885–890.
   PubMed Web of Science ®Google Scholar
• Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245–4249.
   PubMed Web of Science ®Google Scholar
• Lerner AJ, Gustaw-Rothenberg K, Smyth S, et al. Retinoids for treatment of Alzheimer’s disease. Biofactors. 2012;38:84–89.
   PubMed Web of Science ®Google Scholar
• Endres K, Fahrenholz F. Regulation of α-secretase ADAM10 expression and activity. Exp Brain Res. 2012;217:343–352.
   PubMed Web of Science ®Google Scholar
• Koryakina A, Aeberhard J, Kiefer S, et al. Regulation of secretases by all-trans-retinoic acid. FEBS J. 2009;276:2645–2655.
   PubMed Web of Science ®Google Scholar
• Castor TP Combination therapeutics and methods for the treatment of neurodegenerative and other diseases. WO2014085494. 2014.
   Google Scholar
• Goodman AB, Pardee AB. Evidence for defective retinoid transport and function in late onset Alzheimer’s disease. Proc Natl Acad Sci U S A. 2003;100:2901–2905.
   PubMed Web of Science ®Google Scholar
• Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science. 2012;335:1503–1506.
   PubMed Web of Science ®Google Scholar
• Kawahara K, Suenobu M, Shudo K Médicament de traitement de la maladie d’alzheimer. WO20141999905A1. 2014.
   Google Scholar
• Jung YW, Hysolli E, Kim KY, et al. Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies. Curr Opin Neurol. 2012;25:125–130.
   PubMed Web of Science ®Google Scholar
• Lee J, Lee TT, Lee U, et al. Generation of neural stem cells from human trophoblast stem cells. CN103561751. 2014.
   Google Scholar
• Gudas LJ, Benoit Y, Perez R, et al. Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists. WO2014113695A1. 2014.
   Google Scholar
• Barth JH, Macdonald-Hull SP, Mark J, et al. Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol. 1993;129:704–707.
   PubMed Web of Science ®Google Scholar
• Cisneros FJ, Gough BJ, Patton RE, et al. Serum levels of albumin, triglycerides, total protein and glucose in rats are altered after oral treatment with low doses of 13-cis-retinoic acid or all-trans-retinoic acid. J Appl Toxicol. 2005;25:470–478.
   PubMed Web of Science ®Google Scholar
• Stoll D, Binnert C, Mooser V, et al. Short-term administration of isotretinoin elevates plasma triglyceride concentrations without affecting insulin sensitivity in healthy humans. Metabolism. 2004;53:4–10.
   PubMed Web of Science ®Google Scholar
• Li Y, Hashimoto Y, Agadir A, et al. Identification of a novel class of retinoic acid receptor beta-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells. J Biol Chem. 1999;274:15360–15366.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Martin PJ, Storb RF, et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood. 2014;124:287–295.
   PubMed Web of Science ®Google Scholar
• Hall JA, Cannons JL, Grainger JR, et al. Essential role for retinoic acid in the promotion of CD4(+) T cell effector responses via retinoic acid receptor alpha. Immunity. 2011;34:435–447.
   PubMed Web of Science ®Google Scholar
• Blazar B, Aoyama K, Chandraratna R Treatment of graft-versus-host disease disorders using rar antagonists. US20140194517A1. 2014.
   Google Scholar
• Kimura K Therapeutic agent for keratoconjunctive disorders. EP2918290A1. 2015.
   Google Scholar
• Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol. 2004;34:9–19.
   PubMed Web of Science ®Google Scholar
• Situnayake RD, Crump BJ, Thurnham DI, et al. Lipid peroxidation and hepatic antioxidants in alcoholic liver disease. Gut. 1990;31:1311–1317.
   PubMed Web of Science ®Google Scholar
• Bataller R, Brenner DA. Liver fibrosis. J Clin Investig. 2005;115:209–218.
   PubMed Web of Science ®Google Scholar
• Menon KVN, Gores GJ, Shah VH. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clinic Proc. 2001;76:1021–1029.
   PubMed Web of Science ®Google Scholar
• Gramenzi A, Caputo F, Biselli M, et al. Review article: alcoholic liver disease–pathophysiological aspects and risk factors. Aliment Pharmacol Ther. 2006;24:1151–1161.
   PubMed Web of Science ®Google Scholar
• Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol. 2009;27:147–163.
   PubMed Web of Science ®Google Scholar
• Nagy LE. The role of innate immunity in alcoholic liver disease. Alcohol Res Curr Rev. 2015;37:237–250.
   Web of Science ®Google Scholar
• Chaturvedi VK Prevention and treatment of inflammatory conditions. US20140187504A1. 2014.
   Google Scholar
• Hutton CW. Osteoarthritis: the cause not result of joint failure? Ann Rheum Dis. 1989;48:958–961.
   PubMed Web of Science ®Google Scholar
• Pehlivan Y, Kisacik B, Sayiner ZA, et al. Inflammatory back pain in patients treated with isotretinoin. J Rheumatol. 2011;38:2690.
   PubMed Web of Science ®Google Scholar
• Davies MR, Ribeiro LR, Downey-Jones M, et al. Ligands for retinoic acid receptors are elevated in osteoarthritis and may contribute to pathologic processes in the osteoarthritic joint. Arthritis Rheum. 2009;60:1722–1732.
   PubMed Web of Science ®Google Scholar
• Bleisch TJ, Coates DA, Hughes NE, et al. Substituted pyrazole analogs as RAR antagonists. US20140275049A1. 2014.
   Google Scholar
• Masso Gonzalez EL, Patrignani P, Tacconelli S, et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62:1592–1601.
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Rodriguez LG, et al. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. Pharmacol Rep. 2010;62:530–535.
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Pacifici M Composition and method for muscle repair and regeneration. US20140303223A1. 2014.
   Google Scholar
• Ameer GA, Kibbe M, Webb A Controlled and localized release of retinoids to improve neointimal hyperplasia. US20150071984A1 2015.
   Google Scholar
• Geria AN, Lawson CN, Halder RM. Topical retinoids for pigmented skin. J Drugs Dermatol. 2011;10:483–489.
   PubMed Web of Science ®Google Scholar
• Shah KA, Date AA, Joshi MD, et al. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm. 2007;345:163–171.
   PubMed Web of Science ®Google Scholar
• Patel VB, Misra A, Marfatia YS. Topical liposomal gel of tretinoin for the treatment of acne: research and clinical implications. Pharm Dev Technol. 2000;5:455–464.
   PubMed Web of Science ®Google Scholar
• Djedour A, Microcapsules containing retinoids, method of preparing same, and pharmaceutical compositions containing same. US20150190372A1. 2015.
   Google Scholar
• Duprat A Aqueous-gel-type topical compositions in the form of a homogenous suspension of an active principle of the class of retinoids containing at least one hydrophobic silica. US20150150974A1. 2015.
   Google Scholar
• Djedour A Dermatological composition comprising oleosomes and retinoids, process for preparing the same and use thereof. US20150147403A1. 2015.
   Google Scholar
• Johnson AT, Klein ES, Gillett SJ, et al. Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors. J Med Chem. 1995;38:4764–4767.
   PubMed Web of Science ®Google Scholar
• Klein ES, Pino ME, Johnson AT, et al. Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists. J Biol Chem. 1996;271:22692–22696.
   PubMed Web of Science ®Google Scholar
• Teng M, Duong TT, Klein ES, et al. Identification of a retinoic acid receptor alpha subtype specific agonist. J Med Chem. 1996;39:3035–3038.
   PubMed Web of Science ®Google Scholar